pubmed-article:17483874 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17483874 | lifeskim:mentions | umls-concept:C0013203 | lld:lifeskim |
pubmed-article:17483874 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
pubmed-article:17483874 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
pubmed-article:17483874 | lifeskim:mentions | umls-concept:C0301869 | lld:lifeskim |
pubmed-article:17483874 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:17483874 | pubmed:dateCreated | 2007-6-15 | lld:pubmed |
pubmed-article:17483874 | pubmed:abstractText | The ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a major obstacle for successful anticancer therapy. One major mechanism of resistance involves cellular drug efflux by expression of P-glycoprotein (P-gp), a membrane transporter with a wide variety of substrates. Anthracyclines are especially prone to induction of resistance by the P-gp mechanism. P-gp mediated resistance is often confronted by use of P-gp inhibitors, synthesis of novel analogs, or conjugating drugs to macromolecular carriers in order to circumvent the efflux mechanism. In this report, the effect of free and Elastin-like polypeptide (ELP) bound doxorubicin (Dox) on the viability of sensitive (MES-SA and MCF-7) and multidrug resistant (MES-SA/Dx5 and NCI/ADR-RES) human carcinoma cells was studied in vitro. The resistant MES-SA/Dx5 cells demonstrated about 70 times higher resistance to free Dox than the sensitive MES-SA cells, and the NCI/ADR-RES cells were about 30 fold more resistant than the MCF-7 cells. However, the ELP-bound Dox was equally cytotoxic in both sensitive and resistant cell lines. The ELP-bound Dox was shown to accumulate in MES-SA/Dx5 cells, as opposed to free Dox, which was rapidly pumped out by the P-gp transporter. Since ELP is a thermally responsive carrier, the effect of hyperthermia on the cytotoxicity of the ELP-Dox conjugate was investigated. Both cytotoxicity and apoptosis were enhanced by hyperthermia in the Dox resistant cells. The results suggest that ELP-Dox conjugates may provide a means to thermally target solid tumors and to overcome drug resistance in cancer cells. | lld:pubmed |
pubmed-article:17483874 | pubmed:language | eng | lld:pubmed |
pubmed-article:17483874 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17483874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17483874 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17483874 | pubmed:month | Aug | lld:pubmed |
pubmed-article:17483874 | pubmed:issn | 0167-6997 | lld:pubmed |
pubmed-article:17483874 | pubmed:author | pubmed-author:PriebeWaldema... | lld:pubmed |
pubmed-article:17483874 | pubmed:author | pubmed-author:FoktIzabelaI | lld:pubmed |
pubmed-article:17483874 | pubmed:author | pubmed-author:RaucherDrazen... | lld:pubmed |
pubmed-article:17483874 | pubmed:author | pubmed-author:BidwellGene... | lld:pubmed |
pubmed-article:17483874 | pubmed:author | pubmed-author:DavisAisha... | lld:pubmed |
pubmed-article:17483874 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17483874 | pubmed:volume | 25 | lld:pubmed |
pubmed-article:17483874 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17483874 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17483874 | pubmed:pagination | 313-26 | lld:pubmed |
pubmed-article:17483874 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:meshHeading | pubmed-meshheading:17483874... | lld:pubmed |
pubmed-article:17483874 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17483874 | pubmed:articleTitle | A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. | lld:pubmed |
pubmed-article:17483874 | pubmed:affiliation | Department of Biochemistry, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. | lld:pubmed |
pubmed-article:17483874 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17483874 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17483874 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17483874 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17483874 | lld:pubmed |